TAKING STOCK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Therapeutic Antibodies, a bio-babe that suffered the indignity of a difficult stock market birth, gained 27p to 484p as Dr Erling Refsum, the pharmaceutical analyst at Yamaichi, said the shares were "still suffering from some post-float indigestion which makes for a good buying time". He believes the sales potential is high for what are low-risk projects. Because of an unenthusiastic reception the drug developer was forced to cut its value from pounds 150m to pounds 112m to get the issue away. The shares were sold at 525p. There is a suggestion a well-known pharmaceutical personality is about to join the board.
Shell company CRP Leisure continues to seek acquisitions. It currently has one trading asset, theatrical designer Victor Mara. Shares are 2.25p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments